NIH RECOVER
-
Research updates, September 1
People with Long COVID are at a higher risk for cardiovascular, renal, and pulmonary (CRP) outcomes, according to a large observational study published in Journal of the American Heart Association. The study was a retrospective study and assessed more than 2.6 million people who developed COVID-19, comparing about 158,000 people who had been diagnosed with…
-
Research updates, August 11
COVID-19 can reactivate dormant viruses in the body, confirms new research in Nature.
-
Research updates, July 21
The dementia drug donepezil helped decrease fatigue in a subset of people with Long COVID, according to a study published in Frontiers in Pharmacology. In the complex study, which also included testing in mice, Japanese researchers found a majority of people with Long COVID in the cohort had reactivated human herpes virus 6 (HHV-6), which produced…
-
Research updates, July 7
An autopsy study found persistent SARS-CoV-2 virus in the hearts of some people who had died after having COVID-19. A part of the National Institute of Health’s RECOVER program, the researchers shared their unpublished results in a poster at a pathology conference this spring.
-
Research updates, June 9
A new study published in Alzheimer’s and Dementia found more evidence of alterations associated with Alzheimer’s disease in people with Long COVID. Notably, scientists identified a larger choroid plexus, a region of blood vessels in the brain, as well as reduced cerebral blood flow.
-
Why are RECOVER’s first round of Long COVID clinical trials failing?
The U.S.’s flagship Long COVID research program has received over a billion dollars in funding and had years of input from people with the disease. But its first round of clinical trials are failing, at least in the results out so far.
-
RECOVER’s first round of clinical trials are failing. Will the next phase be better?
The NIH studies found that Paxlovid, ivabradine, and computer games did not significantly improve symptoms of Long COVID. Further analysis that may help future research research has not yet been released.
-
Research updates, March 31
The heart failure drug Ivabradine did not significantly improve symptoms for people with Long COVID and postural orthostatic tachycardia syndrome (POTS), according to preliminary results that RECOVER researchers recently shared at a conference.
-
Long COVID affects millions of children. The largest pediatric trial so far launches this year.
One NIH study will test low-dose naltrexone, while other upcoming trials will test larozitide and taurine.
-
New RECOVER-TLC trials won’t enroll until summer. Nearly two years after the program’s launch.
The RECOVER-Treating Long COVID initiative is set to begin enrolling participants in new clinical trials this summer, which will mark nearly two years after the National of Institutes of Health (NIH) effort launched with promises to deliver greater urgency for this chronic disease impacting tens of millions of Americans.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance